New combo therapy aims to fight HPV head and neck cancer before standard treatment
NCT ID NCT07172256
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 38 times
Summary
This study tests a new drug called CUE-101, alone or with another drug (pembrolizumab), in 30 people with newly diagnosed HPV-16 positive head and neck cancer that cannot be easily removed with surgery. The goal is to see if these drugs can boost the immune system to fight the cancer before starting standard treatments like radiation or chemotherapy. The study focuses on safety and how well the immune system responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yale University
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.